2014 Volume 3 Issue 3 Pages 9-13
Sodium ozagrel is an antiplatelet drug administered for acute ischemic stroke. It is eliminated predominantly into the urine and may enhance the antiplatelet effect in patients with renal insufficiency or in patients who are elderly. However, few studies have investigated its use in such patients. Here, we evaluated the effects of sodium ozagrel on the antiplatelet effect in patients with renal insufficiency. The antiplatelet effect was retrospectively determined from the laboratory data of 23 patients receiving sodium ozagrel during the period March 2008 to April 2013. In patients who were not taking aspirin, the adenosine 5′-diphosphate disodium salt (ADP)-induced platelet aggregation threshold index (PATI) and the collagen-induced PATI were respectively 1 μM/mL and 0.7 μg/mL higher in those with renal insufficiency than in those with normal renal function. However, in patients who were taking aspirin, the ADP-induced PATI and the collagen-induced PATI were respectively 0.1 μM/mL lower and 0.2 μg/mL higher in those with renal insufficiency than in those with normal renal function.These findings indicate that sodium ozagrel enhances the antiplatelet effect in renal insufficiency. When administering it to patients with renal insufficiency, physicians should carefully monitor for adverse effects such as digestive hemorrhage and hemorrhagic stroke.